BRIEF — Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045

Oct 13 (Reuters) — Cognition Therapeutics Inc: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (Ct1812) Through 2045 Cognition Therapeutics - Patent Expires In 2045; May Be Extended Up To Five Years Upon Fda Approval Cognition Therapeutics - Fda Meeting Scheduled Next Week For Dlb Program; Manufacturing Planned Q1 2027 Source text:... Further company coverage: CGTX.O (Reuters.Briefs@thomsonreuters.com;)